Cancer vaccines represent an innovative approach in tumor immunology, aiming to activate the immune system to recognize and target cancer cells. These vaccines introduce tumor-associated antigens that stimulate an immune response specifically against cancerous cells. By engaging T cells and other immune components, cancer vaccines help the body identify and destroy tumor cells while sparing healthy tissue. This immunotherapeutic approach is less invasive than traditional cancer treatments, offering potential for fewer side effects. Cancer vaccines are increasingly used alongside therapies like immune checkpoint inhibitors, creating a synergistic effect that can significantly enhance patient outcomes. As research advances, cancer vaccines hold promise for treating various malignancies, marking a shift toward more personalized, targeted, and effective cancer therapies.
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Overcoming biophysical characterization challenges of small antigens in dilute vaccine formulations
Eric Kemp, Merck & Co., United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : A combined LC-MS and immunoassay approach to characterize preservative-induced destabilization of human papillomavirus virus-like particles adsorbed to an aluminum-salt adjuvant
Ria T Caringal, University of Kansas, United States